Antibody-Drug Conjugates Come of Age

The field of ADCs has experienced its fair share of ups-and-downs on the road to clinic and regulatory approvals. Finally, this year we saw the approval of POLIVY™, with several promising ADCs drumming up the excitement in the coming months. To highlight the dynamic landscape, CHI’s Bioconjugates Stream will present a 2-part Antibody-Drug Conjugates program:

Part 1: Engineering Antibody-Drug Conjugates invites scientists to discuss novel design strategies to engineer the right ADC combinations, using novel payloads, new non-IgG platforms, and/or creative linker/conjugation technologies.

Part 2: Clinical Progress of Antibody-Drug Conjugates invites investigators to share their latest results from preclinical to clinical trials, lessons learned from past ADC programs and related fields to inform next-gen ADC design, and to develop better predictability for translation from bench to clinic.

• Engineering Antibody-Drug Conjugates
• Clinical Progress of Antibody-Drug Conjugates

2024 PROGRAMS

View By:

• Display of Biologics
• Engineering Antibodies
• Machine Learning for Protein Engineering

• Antibodies for Cancer Therapy
• Emerging Targets for Oncology
• Antibody Drug Conjugates

• TS: Intro to Bispecifics
• Advancing Bispecific Antibodies
• Engineering Bispecific Antibodies

• Advances in Immunotherapy
• Cell-Based Immunotherapy
• In vivo Cell and Gene Engineering

• Difficult-to-Express Proteins
• Optimizing Protein Expression
• Protein Production Workflows

• Digital Integration in Biotherapeutic Analytics
• Biophysical Methods
• Characterization for Novel Biotherapeutics

• TS: Intro to Immunogenicity
• Immunogenicity Assessment and Management
• TS: Intro to Bioassays

• Emerging Indications for Therapeutic Antibodies
• mRNA Therapeutics
• In vivo Cell and Gene Engineering